Table 1.
Baseline characteristics of the Plasma-HCC cohort and the Serum-HCC cohort.
| Variables | Plasma-HCC Cohort (n = 52) | Serum-HCC Cohort (n = 91) | |
|---|---|---|---|
| HCC (n = 52) | Healthy Control (n = 28) |
HCC (n = 73) | |
| Age (years), mean ± SD | 54.22 ± 9.98 | 34.96 ± 8.18 | 54.62 ± 9.06 |
| Male sex, n (%) | 47 (85.5) | 3 (10.7) | 57 (78.1) |
| AST, IU/mL | 72.73 ± 77.36 | 16.82 ± 4.06 | 73.81 ± 92.28 |
| ALT, IU/mL | 46.11 ± 32.85 | 14.14 ± 7.77 | 49.48 ± 63.53 |
| Platelet, x109/L | 161.59 ± 82.04 | 314± 63.33 | 169.85 ± 85.41 |
| AFP (ng/mL), mean ± SD | 8000.26 ± 17,325.08 | 1.65 ± 0.58 | 4394.77 ± 14,600.73 |
| Etiology, n HBV/HCV/alcohol/others |
– | 65/4/3/1 | |
| Albumin (g/L), mean ± SD | 4.07 ± 0.60 | 4.23 ± 0.55 | |
| Bilirubin (mg/dL), mean ± SD | 1.22 ± 1.81 | 1.49 ± 3.91 | |
| INR, mean ± SD | 1.16 ± 0.14 | 1.18 ± 0.19 | |
| Modified UICC stage, n (%) | – | 26 (36)/9 (12)/20 (27)/11 (15.4)/7 (9.6) | |
| I/II/III/IVa/IVb | |||
| Metastasis, n (%) | 25 (48.1)/27 (51.9) | 7 (9.6)/66 (90.4) | |
| Yes/No | |||
| Vascular invasion, n (%) | – | 29 (54.7)/24 (45.3) | |
| Yes/No | |||
HCC, hepatocellular carcinoma; AST, aspartate transaminase; ALT, alanine transaminase; AFP, alpha-feto protein; HBV, hepatitis B virus; HCV, hepatitis C virus; INR, international normalized ratio; UICC, Union for International Cancer Control; ⎻ Dashes denote lack of reliable data.